Angeles Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$655K Buy
4,286
+1,086
+34% +$166K 0.04% 185
2025
Q4
$441K Buy
3,200
+545
+21% +$71.4K 0.02% 232
2025
Q3
$340K Sell
2,655
-30
-1% -$3.66K 0.02% 240
2025
Q2
$325K Buy
2,685
+567
+27% +$63.9K 0.02% 247
2025
Q1
$236K Sell
2,118
-1,131
-35% -$120K 0.02% 261
2024
Q4
$316K Buy
3,249
+110
+4% +$11.7K 0.03% 199
2024
Q3
$361K Sell
3,139
-162
-5% -$18.4K 0.03% 170
2024
Q2
$351K Sell
3,301
-195
-6% -$19.6K 0.03% 160
2024
Q1
$338K Buy
3,496
+14
+0.4% +$1.44K 0.03% 159
2023
Q4
$352K Buy
3,482
+228
+7% +$22K 0.04% 136
2023
Q3
$331K Buy
3,254
+365
+13% +$37K 0.05% 118
2023
Q2
$292K Buy
2,889
+90
+3% +$9K 0.04% 144
2023
Q1
$258K Sell
2,799
-310
-10% -$27.1K 0.04% 148
2022
Q4
$282K Buy
+3,109
New +$262K 0.05% 137
2022
Q2
Sell
-2,978
Closed -$261K 211
2022
Q1
$261K Buy
+2,978
New +$258K 0.05% 143

Other funds holding NVS

Angeles Wealth Management's NVS Position: Q1 2026 in Review

Angeles Wealth Management increased its Novartis (NVS) stake by 34% in Q1 2026, buying an estimated $166K and bringing the position to 4,286 shares worth $655K. The position accounts for 0.04% of the portfolio, ranked #185.

Angeles Wealth Management first reported a position in NVS in Q1 2022 and has held it in 15 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Angeles Wealth Management held 4,286 shares of Novartis worth $655K as of Q1 2026.
  • Angeles Wealth Management bought 1,086 Novartis shares in Q1 2026, an estimated $166K.
  • Novartis made up 0.04% of Angeles Wealth Management's portfolio in Q1 2026, its #185 holding.
  • Angeles Wealth Management first reported a position in Novartis in Q1 2022 and has held it in 15 quarters since.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Angeles Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.